Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?
09:47am, Monday, 21'st Mar 2022
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price
Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation
12:48pm, Friday, 11'th Mar 2022
The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.
Allogene Therapeutics Inc. (NASDAQ: ALLO) Shares Might Go Down -78.03% This Year
04:00pm, Wednesday, 09'th Mar 2022 Marketing Sentinel
In the last trading session, 1.89 million shares of the Allogene Therapeutics Inc. (NASDAQ:ALLO) were traded, and its beta was 0.90. Most recently the company’s share price was $8.16, and it changed around $0.14 or 1.75% from the last close, which brings the market valuation of the company to $1.25B. ALLO currently trades at a … Allogene Therapeutics Inc. (NASDAQ: ALLO) Shares Might Go Down -78.03% This Year Read More »
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies
12:20pm, Thursday, 24'th Feb 2022
Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading.
Allogene Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
09:09am, Thursday, 24'th Feb 2022 Seeking Alpha
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2021 Results - Earnings Call Transcript
04:42am, Thursday, 24'th Feb 2022 Seeking AlphaAllogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2021 Results - Earnings Call Transcript
11:42pm, Wednesday, 23'rd Feb 2022
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2021 Results - Earnings Call Transcript
Allogene Therapeutics GAAP EPS of -$0.54 beats by $0.06, revenue of $51M
09:26pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Allogene Therapeutics press release (ALLO): Q4 GAAP EPS of -$0.54 beats by $0.06.Revenue of $51K.The Company had $810 million in cash, cash equivalents, and investments as of…
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
09:02pm, Wednesday, 23'rd Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2021.
Allogene Therapeutics Q4 2021 Earnings Preview
10:35pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
Allogene Therapeutics (NASDAQ:ALLO) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is -$0.59
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
01:30pm, Wednesday, 16'th Feb 2022 GlobeNewswire
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
08:30am, Wednesday, 16'th Feb 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
Allogene Therapeutics (ALLO) Investor Presentation (Slideshow)
05:55pm, Friday, 28'th Jan 2022 Seeking AlphaAllogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
08:30am, Wednesday, 26'th Jan 2022
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch
02:56pm, Tuesday, 18'th Jan 2022
Check out these health care firms taking center stage in the stock market now.
